Brief: Poxel Announces PXL065 Granted FDA Fast Track Designation For X-Linked Adrenoleukodystrophy

Poxel SA

16/02/2022 19:19

Feb 16 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL ANNOUNCES PXL065 GRANTED FDA FAST TRACK DESIGNATION
FOR
X-LINKED ADRENOLEUKODYSTROPHY
    * POXEL SA - PHASE 2A CLINICAL POC BIOMARKER STUDY FOR
PXL065 IN
X-LINKED ALD IS ANTICIPATED TO BEGIN MIDYEAR, FOLLOWED BY
RESULTS IN EARLY 2023

Source text for Eikon:  ID:nBwcfsdWQa 
Further company coverage:  POXEL.PA 

 ((Reuters.Briefs@thomsonreuters.com;))